Home
report store
chemotherapy induced peripheral neuropathy epidemiology forecast

Chemotherapy-induced peripheral neuropathy - Epidemiology Forecast - 2036

Published Date : 2026

Pages : 76

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

chemotherapy induced peripheral neuropathy epidemiology forecast

Key Highlights

According to DelveInsight’s analysis, the total incident cases of CINP were approximately 1.6 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
CIPN represents both an acute and chronic complication of chemotherapy, with a substantial proportion of patients developing persistent and often debilitating neuropathic pain.
CIPN is generally not classified as a life-threatening toxicity, but rather as a quality-of-life-limiting adverse effect, which influences therapeutic prioritization in drug development. This distinction contributes to limited pharmaceutical investment, as there is a persistent concern that adjunctive therapies for CIPN could potentially interfere with the efficacy of anticancer regimens or, in the worst case, promote tumor progression.
At present, there is no standardized criterion for the assessment of CIPN, and existing evaluation methods remain limited by inherent shortcomings. Patient-reported outcomes are often considered the most reliable indicators, as clinician-based assessments tend to underestimate the true burden and severity of toxicity.
CIPN remains a significant unmet need due to its complex and heterogeneous pathobiology involving peripheral and central mechanisms. This variability has hindered the identification of consistent therapeutic targets, leaving management largely symptomatic.

Chemotherapy-induced Peripheral Neuropathy (CIPN) Epidemiology Forecast in the 7MM

2025 Incident Cases of Chemotherapy-induced Peripheral Neuropathy (CIPN): ~1.6 million
2036 Projected Incident Cases of Chemotherapy-induced Peripheral Neuropathy (CIPN): ~1.8 million
Chemotherapy-induced Peripheral Neuropathy (CIPN) Growth Rate (2026–2036): 1.0 % CAGR

DelveInsight's ‘Chemotherapy-induced Peripheral Neuropathy (CIPN) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Chemotherapy-induced Peripheral Neuropathy (CIPN), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	North America: The US; Europe: Germany, France, Italy, Spain, and the UK; Asia-Pacific: Japan
CIPN Epidemiology CAGR (Forecast period)	1.0% (2026–2036)
CIPN Epidemiology Segmentation Analysis	Patient Burden Assessment Total Incident Population of CIPN Severity-specific Incident Population of CIPN Incident Population of CIPN by Cancer Type Total Treated Population of CIPN

Chemotherapy-induced Peripheral Neuropathy (CIPN) Understanding and Diagnosis

Chemotherapy-induced Peripheral Neuropathy (CIPN) Overview

Cancer remains a leading cause of global mortality, with rising incidence and improved survival driven by advances in early detection and frontline chemotherapy; however, CIPN has emerged as a common and clinically significant toxicity affecting up to 90% of patients treated with agents such as platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors. Widely used across cancers, including breast, colorectal, prostate, and hematological malignancies, these therapies can induce neurotoxicity characterized by distal axonal degeneration and functional neuronal alterations, leading to persistent sensory symptoms such as tingling, numbness, burning pain, and a “glove and stocking” distribution. CIPN may last for months or years, significantly impairing quality of life and contributing to psychological distress, and in severe cases, necessitating dose reduction or discontinuation of chemotherapy, potentially compromising treatment efficacy and clinical outcomes.

Further details are provided in the report.

Diagnosis

There is no standardized method for diagnosing CIPN, so assessment relies on clinical evaluation, including patient history, symptoms, neurological examination, and chemotherapy exposure. Objective tools such as nerve conduction studies (NCS) detect reduced sensory and motor amplitudes, while quantitative sensory testing (QST) assesses small fiber dysfunction. Subjective measures include clinician-graded scales (e.g., NCI-CTCAE) and patient-reported tools (e.g., EORTC QLQ-CIPN20), which better capture symptom burden but may miss early changes. Emerging biomarkers like neurofilament light chain (NfL), microRNAs, and ABCB1 variants show potential for early detection, though they remain under validation.

Further details are provided in the report.

Chemotherapy-induced Peripheral Neuropathy (CIPN) Epidemiology

Key Findings from Chemotherapy-induced Peripheral Neuropathy (CIPN) Epidemiological Analysis and Forecast

According to DelveInsight’s estimates, in 2025, the total number of incident cases of CIPN in the 7MM was ~1.6 million.
In the US, among severity-specific incident cases of CIPN, severe CIPN accounted for the majority of cases (~239,600), followed by mild (~208,550) and moderate (~199,500) in 2025.
In 2025, breast and colorectal cancers accounted for the majority share of CIPN incidence across the EU4 and the UK. Breast cancer was associated with ~123,450 CIPN cases, and colorectal cancer contributed ~118,600 cases.
The likelihood of developing CIPN is strongly influenced by the extent of chemotherapy use, with higher utilization seen in cancers such as hematologic malignancies, lung, and gastric cancers. This makes chemotherapy exposure, rather than cancer incidence alone, a critical determinant of CIPN burden. As treatment intensity and duration increase, the risk of neuropathy correspondingly rises.

Scope of the Report

The report covers a segment of key events, an executive summary, a descriptive overview of Chemotherapy-induced Peripheral Neuropathy (CIPN), explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Chemotherapy-induced Peripheral Neuropathy (CIPN) Patient Population Forecast

Report Key Strengths

Epidemiology-based (Epi-based) Bottom-up Forecasting
Artificial Intelligence (AI)-Enabled Market Research Report
11-Year Forecasts

FAQs

What are the disease risks, burdens, and unmet needs of Chemotherapy-induced Peripheral Neuropathy (CIPN)? What will be the growth opportunities across the 7MM concerning the patient population with Chemotherapy-induced Peripheral Neuropathy (CIPN)?
What is the historical and forecasted Chemotherapy-induced Peripheral Neuropathy (CIPN) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.

List of Tables:

List of Table

Table 1: Summary of CIPN Epidemiology

Table 2: Common Signs and Symptoms Observed in Patients With CIPN

Table 3: Grading Scales for CIPN

Table 4: Patient-reported Outcome Measures

Table 5: Prevention Guidelines for CIPN

Table 6: Grading Table

Table 7: Levels of Evidence

Table 8: Grades of Recommendation

Table 9: Total Incident Population of CIPN in the 7MM (2022–2036)

Table 10: Total Incident Population of CIPN in the United States (2022–2036)

Table 11: Severity-specific Incident Population of CIPN in the United States 2022–2036)

Table 12: Incident Population of CIPN by Cancer Type in the United States (2022–2036)

Table 13: Total Treated Population of CIPN in the United States (2022–2036)

Table 14: Total Prevention Population of CIPN in the United States (2022–2036)

Table 15: Total Incident Population of CIPN in EU4 and the UK (2022–2036)

Table 16: Severity-specific Incident Population of CIPN in Germany (2022–2036)

Table 17: Severity-specific Incident Population of CIPN in France (2022–2036)

Table 18: Severity-specific Incident Population of CIPN in Italy (2022–2036)

Table 19: Severity-specific Incident Population of CIPN in Spain (2022–2036)

Table 20: Severity-specific Incident Population of CIPN in the UK (2022–2036)

Table 21: Severity-specific Incident Population of CIPN in EU4 and the UK (2022–2036)

Table 22: Incident Population of CIPN by Cancer Type in Germany (2022–2036)

Table 23: Incident Population of CIPN by Cancer Type in France (2022–2036)

Table 24: Incident Population of CIPN by Cancer Type in Italy (2022–2036)

Table 25: Incident Population of CIPN by Cancer Type in Spain (2022–2036)

Table 26: Incident Population of CIPN by Cancer Type in the UK (2022–2036)

Table 27: Incident Population of CIPN by Cancer Type in EU4 and the UK (2022–2036)

Table 28: Total Treated Population of CIPN in EU4 and the UK (2022–2036)

Table 29: Total Prevention Population of CIPN in EU4 and the UK (2022–2036)

Table 30: Total Incident Population of CIPN in Japan (2022–2036)

Table 31: Severity-specific Incident Population of CIPN in Japan (2022–2036)

Table 32: Incident Population of CIPN by Cancer Type in Japan (2022–2036)

Table 33: Total Treated Population of CIPN in Japan (2022–2036)

Table 34: Total Prevention Population of CIPN in Japan (2022–2036)

List of Figures:

List of Figures

Figure 1: Diagnostic Algorithm

Figure 2: Total Incident Population of CIPN in 7MM (2022–2036)

Figure 3: Total Incident Population of CIPN in the United States (2022–2036)

Figure 4: Severity-specific Incident Population of CIPN in the United States (2022–2036)

Figure 5: Incident Population of CIPN by Cancer Type in the United States (2022–2036)

Figure 6: Total Treated Population of CIPN in the United States (2022–2036)

Figure 7: Total Prevention Population of CIPN in the United States (2022–2036)

Figure 8: Total Incident Population of CIPN in EU4 and the UK (2022–2036)

Figure 9: Severity-specific Incident Population of CIPN in EU4 and the UK (2022–2036)

Figure 10: Incident Population of CIPN by Cancer Type in EU4 and the UK (2022–2036)

Figure 11: Total Treated Population of CIPN in EU4 and the UK (2022–2036)

Figure 12: Total Prevention Population of CIPN in EU4 and the UK (2022–2036)

Figure 13: Total Incident Population of CIPN in Japan (2022–2036)

Figure 14: Severity-specific Incident Population of CIPN in Japan (2022–2036)

Figure 15: Incident Population of CIPN by Cancer Type in Japan (2022–2036)

Figure 16: Total Treated Population of CIPN in Japan (2022–2036)

Figure 17: Total Prevention Population of CIPN in Japan (2022–2036)

Related Reports

Chemotherapy Induced Peripheral Neuropathy Market Insight, Epidemiology And Market Forecast - 2036

DelveInsight's Chemotherapy-induced peripheral neuropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding..

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast APAC - 2036

DelveInsight’s Chemotherapy-Induced Peripheral Neuropathy APAC Patient Pool Analysis, Market Size and Market Forecast APAC, 2036 report provides a detailed overview of the disease.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027

DelveInsight's 'Chemotherapy-Induced Peripheral Neuropathy (CIPN)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

License Type

Offer